title: Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review.
abstract: Breast cancer remains the most common type of cancer affecting women worldwide with an estimated lifetime risk of 1:8. With developments in adjuvant treatment and the identification of breast cancer subtypes, rising expectation of 'personalized' and 'targeted' therapy, decisions on systemic therapy have become increasingly more difficult. In a bid to assist clinicians in correctly selecting patients in whom systemic adjuvant therapy would be of most benefit, a number of decision-making tools have been developed. In this article, the authors will review some of these tools, explore how they were developed and assess the impact they have had on daily clinical practice.
authors.affiliation: SW Wales Cancer Institute, Department of Oncology, Singleton Hospital, Sketty Lane, Swansea, SA2 8QA, UK.
authors.forename: Asmaa
authors.initials: A
authors.lastname: Al-Allak
authors.forename: Paul D
authors.initials: PD
authors.lastname: Lewis
authors.forename: Gianfilippo
authors.initials: G
authors.lastname: Bertelli
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003657:Decision Making; D005260:Female; D005820:Genetic Testing; D017408:Guidelines as Topic; D006801:Humans; D020407:Internet; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D047072:Aromatase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human